- Report
- April 2022
- 250 Pages
Asia Pacific
From €2393EUR$2,490USD£2,052GBP
- Report
- December 2022
- 112 Pages
Global
From €4710EUR$4,900USD£4,039GBP
- Report
- October 2022
- 118 Pages
Global
From €4710EUR$4,900USD£4,039GBP
- Report
- February 2018
- 103 Pages
Global
From €3364EUR$3,500USD£2,885GBP
- Report
- June 2019
- 130 Pages
United States
€2879EUR$2,995USD£2,469GBP
- Report
- July 2023
- 140 Pages
Global
From €5766EUR$5,999USD£4,945GBP
- Report
- August 2020
- 142 Pages
Global
From €4325EUR$4,500USD£3,709GBP
- Report
- July 2022
- 280 Pages
Global
From €5545EUR$5,769USD£4,755GBP
- Report
- May 2023
- 147 Pages
Global
From €5766EUR$5,999USD£4,945GBP
- Book
- October 2020
- 288 Pages
- Book
- October 2019
- 632 Pages
- Book
- April 2018
- 776 Pages
United States
- Book
- January 2016
- 368 Pages
Cervical cancer is a type of cancer that affects the cells of the cervix, the lower part of the uterus that connects to the vagina. It is the fourth most common cancer in women worldwide, and is caused by the human papillomavirus (HPV). Treatment for cervical cancer typically involves surgery, radiation therapy, chemotherapy, and targeted therapy.
The cervical cancer market is a subset of the larger oncology market, which is composed of drugs, diagnostics, and services used to treat cancer. The cervical cancer market is expected to grow due to the increasing prevalence of HPV, the development of new treatments, and the increasing availability of healthcare services.
Some companies in the cervical cancer market include Merck, Bristol-Myers Squibb, AstraZeneca, Roche, and Novartis. Show Less Read more
